Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on October 25, 2016. The report discloses positive survival results from the final analysis of the Phase 2 Borealis-2 clinical trial for the investigational drug apatorsen in combination with docetaxel for metastatic bladder cancer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial outcomes and does not contain financial statements.
Material Changes and Clinical Results
- Trial Scope: The Borealis-2 trial enrolled 200 patients with metastatic bladder cancer who had progressed following first-line platinum-based chemotherapy.
- Primary Outcome: Patients receiving apatorsen plus docetaxel experienced a 20% reduction in the risk of death compared to those receiving docetaxel alone.
- Statistical Data: Hazard Ratio (HR) of 0.80; 95% Confidence Interval (CI) of 0.65-0.98; p-value of 0.078.
- Study Design: Conducted by the Hoosier Cancer Research Network at 28 U.S. sites using a stratified log-rank test at a one-sided 0.10 significance level.
Outlook, Risks, and Management Commentary
Management highlighted the positive nature of the survival results. The filing does not explicitly state future guidance, specific risks, or contingencies beyond the standard disclosure of the trial results. The p-value of 0.078 indicates the result did not meet the conventional two-sided 0.05 significance threshold, though the trial was designed with a one-sided 0.10 significance level.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for additional context on the statistical analysis.
- Confirm the specific definition of the "one-sided 0.10 significance level" used in the trial protocol.
- Review subsequent filings for updates on regulatory strategy or potential Phase 3 trial initiation based on these results.
- Check the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.